BioSpace News Archive

Boston Pharmaceuticals licensed the drug candidate BOS-580, an injectable, genetically engineered variant of human FGF21.

Gilead Sciences and Jounce Therapeutics entered a discovery and development deal to exclusively license Jounce’s JTX-1811 immuno-oncology program.

A new 10,000 square foot facility in Marlborough, MA will allow StageBio to offer their expanded histopathology expertise and grow the company’s reach across the greater Boston region.

- Launches Strategic Growth Initiative of Expanded Late-stage Oncology Pipeline - [01-September-2020] SAN DIEGO , Sept. 1, 2020 /PRNewswire/ -- Kintara Therapeutics, Inc. (“Kintara” or the “Company”) (Nasdaq: KTRA) announced today the final closing of its previously announced private placement of Series C Convertible Preferred Stock (the “Preferred Stock”) to accredit

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced plans to develop a program to scientifically evaluate and facilitate clinical trials on the efficacy of decitabine and cedazuridine

Amyris, Inc., a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, announced that it has successfully scaled up the commercial production of Cannabigerol leveraging its industrial fermentation process capability.

Descartes-30 engineered to express a unique combination of DNases to eliminate neutrophil extracellular traps (NETs), a key driver of inflammation and clotting in ARDS.

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that management is scheduled to present and conduct one-on-one meetings at the H.C. Wainwright 22 nd Annual Global Investment Conference to be held virtually on September 14th-16th. Anthony DiTonno, Chief Executive Officer, is schedule

Sherlock Biosciences, an Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable, today reported data from a 20 clinical sample pilot study conducted by Gregory J. Tsongalis, Ph.D., and his team at Dartmouth-Hitchcock Medical Center in Leban

Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing innovative targeted biologic drugs, announced today that it has successfully completed a preclinical Severe Combined Immunodeficient